...
search icon
advm-img

Adverum Biotechnologies Inc, Common Stock

ADVM

NAQ

$4.46

+$0.17

(3.96%)

1D
Industry: Biotechnology Sector: Health Care

Analyst Forecast

Price Chart

Key Metrics

Market Cap info-icon
This is a company’s total value as determined by the stock market. It is calculated by multiplying the total number of a company's outstanding shares by the current market price of one share.
$92.78M
P/E Ratio info-icon
This is the ratio of a security’s current share price to its earnings per share. This ratio determines the relative value of a company’s share.
0
Volume info-icon
This is the total number of shares traded during the most recent trading day.
80.81K
Avg Volume info-icon
This is the average number of shares traded during the most recent 30 days.
0
Dividend Yield info-icon
This ratio shows how much income you earn in dividend payouts per year for every dollar invested in the stock (or the stock’s annual dividend payment expressed as a percentage of its current price).
0.00%
Beta info-icon
This measures the expected move in a stock’s price relative to movements in the overall market. The market, such as the S&P 500 Index, has a beta of 1.0. If a stock has a Beta greater (or lower) than 1.0, it suggests that the stock is more (or less) volatile than the broader market.
1.01
52-week Range info-icon
This shows the range of the stock’s price between the 52-week high (the highest price of the stock for the past 52 weeks) and the 52-week low (the lowest price of the stock for the past 52 weeks).
$3.85 L
$22.4 H
$4.46

About Adverum Biotechnologies Inc, Common Stock

Adverum Biotechnologies, Inc., a clinical-stage company, develops gene therapy product candidates to treat ocular diseases. Its lead product candidate is ixoberogene soroparvovec (ADVM-022), a single intravitreal injection gene therapy candidate used for the treatment of patients with wet age-related macular degeneration and diabetic macular edema which is in phase 2 clinical trials. The company is developing ADVM-062 (AAV.7m8-L-opsin), a novel gene therapy product candidate for the treatment of blue cone monochromacy via a single IVT injection. Adverum Biotechnologies, Inc. has license and collaboration agreements with University of California; GenSight Biologics; Lexeo Therapeutics; and Virovek, Inc. The company was formerly known as Avalanche Biotechnologies, Inc. and changed its name to Adverum Biotechnologies, Inc. in May 2016. Adverum Biotechnologies, Inc. was incorporated in 2006 and is headquartered in Redwood City, California. more

Industry: BiotechnologySector: Health Care

Returns

Time FrameADVMSectorS&P500
1-Week Return3.72%-0.03%1.53%
1-Month Return4.94%4.56%4.75%
3-Month Return-38.48%1.29%2.77%
6-Month Return-30.85%-3.54%12.18%
1-Year Return-78.76%1.59%22.34%
3-Year Return-67.91%13.55%38.91%
5-Year Return-97.18%40.85%80.7%
10-Year Return-98.79%105.52%190.95%

Financials

Dec '19Dec '20Dec '21Dec '22Dec '235YR TREND
Total Revenue250.00K7.50M7.50M3.60M3.60M[{"date":"2019-12-31","value":3.33,"profit":true},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":48,"profit":true},{"date":"2023-12-31","value":48,"profit":true}]
Cost of Revenue40.42M4.16M4.64M6.53M5.64M[{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":10.29,"profit":true},{"date":"2021-12-31","value":11.49,"profit":true},{"date":"2022-12-31","value":16.15,"profit":true},{"date":"2023-12-31","value":13.96,"profit":true}]
Gross Profit250.00K(4.16M)2.85M(6.53M)(2.04M)[{"date":"2019-12-31","value":8.76,"profit":true},{"date":"2020-12-31","value":-145.64,"profit":false},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":-228.65,"profit":false},{"date":"2023-12-31","value":-71.59,"profit":false}]
Gross Margin100.00%(55.44%)38.07%(181.33%)(56.78%)[{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":-55.44,"profit":false},{"date":"2021-12-31","value":38.07,"profit":true},{"date":"2022-12-31","value":-181.33,"profit":false},{"date":"2023-12-31","value":-56.78,"profit":false}]
Operating Expenses68.80M117.95M153.62M157.13M127.59M[{"date":"2019-12-31","value":43.78,"profit":true},{"date":"2020-12-31","value":75.06,"profit":true},{"date":"2021-12-31","value":97.76,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":81.2,"profit":true}]
Operating Income(68.55M)(117.95M)(146.12M)(157.13M)(123.99M)[{"date":"2019-12-31","value":-6854500000,"profit":false},{"date":"2020-12-31","value":-11795000000,"profit":false},{"date":"2021-12-31","value":-14612200000,"profit":false},{"date":"2022-12-31","value":-15713500000,"profit":false},{"date":"2023-12-31","value":-12399100000,"profit":false}]
Total Non-Operating Income/Expense-----[{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}]
Pre-Tax Income(64.49M)(116.39M)(145.54M)(154.46M)(118.24M)[{"date":"2019-12-31","value":-6448600000,"profit":false},{"date":"2020-12-31","value":-11639300000,"profit":false},{"date":"2021-12-31","value":-14554000000,"profit":false},{"date":"2022-12-31","value":-15446200000,"profit":false},{"date":"2023-12-31","value":-11824300000,"profit":false}]
Income Taxes1.40M1.11M4.41M74.00K(1.08M)[{"date":"2019-12-31","value":31.78,"profit":true},{"date":"2020-12-31","value":25.27,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":1.68,"profit":true},{"date":"2023-12-31","value":-24.45,"profit":false}]
Income After Taxes-----[{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}]
Income From Continuous Operations(64.49M)(117.51M)(145.54M)(154.54M)(117.17M)[{"date":"2019-12-31","value":-6448600000,"profit":false},{"date":"2020-12-31","value":-11750700000,"profit":false},{"date":"2021-12-31","value":-14554000000,"profit":false},{"date":"2022-12-31","value":-15453600000,"profit":false},{"date":"2023-12-31","value":-11716500000,"profit":false}]
Income From Discontinued Operations-----[{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}]
Net Income(64.49M)(117.51M)(145.54M)(154.54M)(117.17M)[{"date":"2019-12-31","value":-6448600000,"profit":false},{"date":"2020-12-31","value":-11750700000,"profit":false},{"date":"2021-12-31","value":-14554000000,"profit":false},{"date":"2022-12-31","value":-15453600000,"profit":false},{"date":"2023-12-31","value":-11716500000,"profit":false}]
EPS (Diluted)(1.00)(1.37)(1.48)(1.55)(3.23)[{"date":"2019-12-31","value":-100,"profit":false},{"date":"2020-12-31","value":-137,"profit":false},{"date":"2021-12-31","value":-148,"profit":false},{"date":"2022-12-31","value":-155,"profit":false},{"date":"2023-12-31","value":-323,"profit":false}]

Ratios

Liquidity

These ratios help you determine the liquidity of the company. Higher is better.

ADVM
Cash Ratio 5.54
Current Ratio 5.82

Asset Efficiency

These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.

ADVM
ROA (LTM) -29.83%
ROE (LTM) -76.26%

Liabilities

These ratios help you understand the company's liabilities, gauging the riskiness of the investment.

ADVM
Debt Ratio Lower is generally better. Negative is bad. 0.39
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. 0.61

Valuation

These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.

ADVM
Trailing PE NM
Forward PE NM
P/S (TTM) 92.78
P/B 0.62
Price/FCF NM
EV/R 9.26
EV/Ebitda 0.10
PEG NM

FAQs

What is Adverum Biotechnologies Inc share price today?

Adverum Biotechnologies Inc (ADVM) share price today is $4.46

Can Indians buy Adverum Biotechnologies Inc shares?

Yes, Indians can buy shares of Adverum Biotechnologies Inc (ADVM) on Vested. To buy Adverum Biotechnologies Inc from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in ADVM stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.

Can Fractional shares of Adverum Biotechnologies Inc be purchased?

Yes, you can purchase fractional shares of Adverum Biotechnologies Inc (ADVM) via the Vested app. You can start investing in Adverum Biotechnologies Inc (ADVM) with a minimum investment of $1.

How to invest in Adverum Biotechnologies Inc shares from India?

You can invest in shares of Adverum Biotechnologies Inc (ADVM) via Vested in three simple steps:

  • Click on Sign Up or Invest in ADVM stock at the top of this page
  • Breeze through our fully digital and secure KYC process and open your US Brokerage account in a few minutes
  • Transfer USD funds to your US Brokerage account and start investing in Adverum Biotechnologies Inc shares
What is Adverum Biotechnologies Inc 52-week high and low stock price?

The 52-week high price of Adverum Biotechnologies Inc (ADVM) is $22.4. The 52-week low price of Adverum Biotechnologies Inc (ADVM) is $3.85.

What is Adverum Biotechnologies Inc price-to-book (P/B) ratio?

The price-to-book (P/B) ratio of Adverum Biotechnologies Inc (ADVM) is 0.62

What is the Market Cap of Adverum Biotechnologies Inc?

The market capitalization of Adverum Biotechnologies Inc (ADVM) is $92.78M

What is Adverum Biotechnologies Inc’s stock symbol?

The stock symbol (or ticker) of Adverum Biotechnologies Inc is ADVM

Signup to access all features and start your US investing journey!

  • Open your account in minutes
  • Take your portfolio global, starting at just $1
Get started

Add ticker to compare

Scroll to Top